The immunoscore is considered a very important prognostic factor for disease-free survival, disease-specific survival, and overall survival, especially at early-stage CRC; on the other hand, it has biological and immunological meaning (adaptive immune response to tumors) and provides an implement for selecting novel therapeutic approaches, such as immunotherapy, i.e., anti-CTLA4, anti-PDCD1 (PD-1) and anti-CD274 (PD-L1) [100]. Here, PDCD1 is linked to colorectal carcinoma.